Table 3.

Antimicrobial activities of ceftobiprole and comparator agents when tested against clinical isolates from European medical centres

Pathogen (n)/Antibiotic	MIC (mg/L)			MIC interpretation, % susceptiblea
	Range	MIC50	MIC90
S. aureus (7000)
Ceftobiprole	≤0.015 to 4	0.5	2	99.7
Clindamycin	≤0.03 to >1	0.12	>1	85.3
Daptomycin	≤0.06 to >2	0.5	1	99.6
Erythromycin	≤0.12 to >4	0.5	>4	59.9
Gentamicin	≤0.06 to >2	0.25	0.5	92.3
Levofloxacin	≤0.03 to >4	0.25	>4	59.7
Linezolid	0.25 to >4	2	2	99.9
Tetracycline	≤0.06 to >4	0.25	>4	89.5
Trimethoprim/sulfamethoxazole	≤0.06 to >4	≤0.06	≤0.06	99.7
Vancomycin	≤0.25 to 4	0.5	1	99.9
MSSA (3498)
Ceftobiprole	0.03 to 1	0.5	0.5	100
Clindamycin	≤0.03 to >1	0.12	0.12	97.3
Daptomycin	0.12 to- >2	0.5	1	99.7
Erythromycin	≤0.12 to >4	0.25	>4	80.3
Gentamicin	≤0.06 to >2	0.25	0.5	97.8
Levofloxacin	0.06 to >4	0.25	1	94.0
Linezolid	0.25 to 4	2	2	100
Tetracycline	≤0.06 to >4	0.25	0.25	95.9
Trimethoprim/sulfamethoxazole	≤0.06 to >4	≤0.06	≤0.06	99.9
Vancomycin	≤0.25 to 2	1	1	100
MRSA (3502)
Ceftobiprole	≤0.015 to 4	1	2	99.5
Clindamycin	≤0.03 to >1	0.12	>1	73.4
Daptomycin	≤0.06 to >1	0.5	1	99.5
Erythromycin	≤0.12 to >4	>4	>4	39.3
Gentamicin	≤0.06 to >2	0.25	>2	86.9
Levofloxacin	0.06 to >4	>4	>4	25.5
Linezolid	0.25 to >4	1	2	99.9
Tetracycline	≤0.06 to >4	0.25	>4	83.1
Trimethoprim/sulfamethoxazole	≤0.06 to >4	≤0.06	≤0.06	99.4
Vancomycin	≤0.25 to 4	0.5	1	99.9
S. pneumoniae (3007)
Ceftobiprole	≤0.06 to 4	≤0.06	0.5	97.8
Ampicillin	≤0.03 to >8	0.06	4	86.6
Azithromycin	≤0.03 to >8	0.06	>8	76.4
Ceftriaxone	≤0.015 to >8	0.03	1	99.5
Clindamycin	≤0.015 to >2	0.03	>2	83.9
Imipenem	≤0.015 to >2	≤0.015	0.25	99.4
Levofloxacin	≤0.12 to >8	1	1	99.5
Linezolid	≤0.12 to 2	1	1	100
Penicillin	≤0.06 to >8	≤0.06	2	95.1
Tetracycline	≤0.03 to >8	0.25	>8	79.0
Trimethoprim/sulfamethoxazole	≤0.06 to >8	0.25	8	81.1
Enterobacterales (7197)
Ceftobiprole	≤0.06 to >8	≤0.06	>8	76.3
Amoxicillin/clavulanic acid	0.25 - >64	32	>64	43.9
Ampicillin	≤0.12 to >64	>64	>64	15.4
Cefepime	≤0.008 to >8	0.06	>8	84.8
Ceftazidime	≤0.03 to >8	0.25	>8	80.5
Gentamicin	≤0.12 to >8	0.5	>8	87.5
Imipenem	≤0.03 to >8	0.12	2	96.1
Levofloxacin	≤0.004 to >4	0.06	>4	79.3
Piperacillin/tazobactam	≤0.12 to >32	2	>32	81.3
Trimethoprim/sulfamethoxazole	≤0.12 to >4	≤0.12	>4	74.9
P. aeruginosa (2191)
Ceftobiprole	≤0.06 to >8	4	>8	65.5b
Cefepime	≤0.06 to >32	4	32	77.9
Ceftazidime	0.12 to >32	4	32	73.3
Colistin	0.12 to >32	1	2	99.5
Gentamicin	≤0.06 to >32	2	32	8.0b
Imipenem	≤0.06 to >32	2	32	73.4
Levofloxacin	≤0.06 to >32	1	>32	63.9
Piperacillin	0.12 to >32	8	>32	69.1
Piperacillin/tazobactam	≤0.06 to >32	8	>32	71.9
H. influenzae (605)
Ceftobiprole	≤0.06 to 2	≤0.06	0.5	100b
Amoxicillin/clavulanic acid	0.06 to 64	0.5	4	88.4
Ampicillin	0.06 to >8	0.5	>8	74.5
Ceftriaxone	<0.001 to >0.5	0.004	0.03	95.0
Cefuroxime	≤0.06 to >8	0.5	4	85.5
Chloramphenicol	≤0.12 to >4	0.5	0.5	98.0
Imipenem	≤0.06 to >8	0.5	2	75.1
Levofloxacin	≤0.004 to >4	0.015	0.03	95.7
Tetracycline	≤0.06 to >8	0.25	0.5	99.5
Trimethoprim/sulfamethoxazole	≤0.008 to >4	0.03	4	76.9

MIC_n, MIC for n% of isolates tested.

^aPercentage of susceptible plus susceptible at increased exposure.

^bPK/PD breakpoint was applied.